peptibase
Weight Loss

Exenatide

Also known as: Byetta, Bydureon, Exendin-4

FDA Approved
Share:

Key Facts: Exenatide

Category
Weight Loss
FDA Status
FDA Approved
Clinical Status
FDA Approved - Type 2 diabetes (adults and pediatric 10-17). Brand names Byetta and Bydureon BCise discontinued Oct 2024; generic available (Amneal).
Administration
Subcutaneous injection
Typical Dose
5-10 mcg twice daily or 2 mg weekly
Frequency
Twice daily (IR) or once weekly (ER)
Duration
Long-term / chronic use
Also Known As
Byetta, Bydureon, Exendin-4

Mechanism of Action

Exenatide is a synthetic version of exendin-4 from Gila monster venom. It shares 53% homology with human GLP-1 and resists DPP-4 degradation. Activates GLP-1 receptors to improve glucose control and reduce appetite.

Research Summary

First-in-class GLP-1 agonist with extensive clinical experience since 2005. Studies show 2-4% weight loss and A1C reductions of 0.5-1%. Weekly formulation (Bydureon) provides more consistent levels.

Trial Progress:FDA Approved
Pre
I
II
III
IV
FDA

Dosing Information

FDA Approved·Human clinical trials completed, FDA approved

Typical Dosingⓘ

Community experience

Common Dose

5-10 mcg twice daily or 2 mg weekly

Range

5-10 mcg (IR) or 2 mg (ER)

Frequency

Twice daily (IR) or once weekly (ER)

First GLP-1 approved. Byetta (twice daily) or Bydureon (weekly). Must be injected.

Research Dosingⓘ

Scientific studies

FDA-approved dosing

Doses from Studies

5-10 mcg twice daily (Byetta)

FDA Approved Labeling - Prescribed dose ↗

Duration

Long-term / chronic use

Administration

Subcutaneous injection

Timing & Administration

Best Time to Take

Before bed or morning (fasted)

Follow specific peptide protocol

Food Recommendation

Take on empty stomach

Why This Timing?

GH-related peptides work best on an empty stomach to maximize growth hormone release.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • ●Nausea (common)
  • ●Vomiting
  • ●Diarrhea
  • ●Dizziness
  • ●Hypoglycemia
  • ●Injection site reactions
  • ●Pancreatitis (BOXED WARNING)
  • ●Acute kidney injury
  • ●FDA approved (Byetta, Bydureon)

References

Research This Peptide Further

PubMedClinicalTrials.govFDA.gov

Frequently Asked Questions

What does Exenatide do?

The first GLP-1 receptor agonist approved for diabetes. Derived from Gila monster saliva. Available in twice-daily and weekly formulations.

How does Exenatide work?

Exenatide is a synthetic version of exendin-4 from Gila monster venom. It shares 53% homology with human GLP-1 and resists DPP-4 degradation. Activates GLP-1 receptors to improve glucose control and reduce appetite.

Is Exenatide FDA approved?

Yes, Exenatide is FDA approved. FDA Approved - Type 2 diabetes (adults and pediatric 10-17). Brand names Byetta and Bydureon BCise discontinued Oct 2024; generic available (Amneal).

What are the side effects of Exenatide?

Reported side effects include: Nausea (common), Vomiting, Diarrhea, Dizziness, Hypoglycemia. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Exenatide?

Community-reported common dose: 5-10 mcg twice daily or 2 mg weekly (Twice daily (IR) or once weekly (ER)). Range: 5-10 mcg (IR) or 2 mg (ER). Administration: Subcutaneous injection. Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with Exenatide or used in similar applications.

Semaglutide

FDA

A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.

Weight Loss

Tirzepatide

FDA

A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.

Weight Loss

Orforglipron

FDA

An oral non-peptide GLP-1 receptor agonist. FDA approved April 1, 2026 under the brand name Foundayo - the first daily oral GLP-1 pill for weight loss. Distribution began April 6, 2026. FDA subsequently requested additional post-approval safety data.

Weight Loss

Liraglutide

FDA

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.

Weight Loss

Dulaglutide

FDA

An FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.

Weight Loss

Retatrutide

Clinical Trials

A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.

Weight Loss
How to Use ExenatideExenatide AlternativesCompare with SimilarBrowse All Peptides

Want updates on Exenatide research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Back to all peptides